This Healthcare Tech Stock Rises 29% in 6 Months: What Is Behind the Move?

This healthcare tech stock has added approximately 29% in six months, turning Rs 1 lakh into roughly Rs 1.29 lakh since March 2026. A company that runs clinical and billing operations for US health systems posted a 6-month return of 29.48% as of 10 September 2026, ranking 51st in a screen of 101 large-cap and mid-cap NSE shares.

The company is Inventurus Knowledge Solutions Ltd (NSE: IKS), better known by its brand IKS Health. The Inventurus Knowledge Solutions share price closed at Rs 1,783.70 on 10 September 2026, giving it a market value of approximately Rs 30,749 crore. This healthcare tech stock rose on a strong FY26 earnings run and a large US acquisition in April 2026, though its longer record is less flattering.

Click Here – Get Free Investment Predictions

How Much Has This Healthcare Tech Stock Gained in 6 Months?

This healthcare tech stock has gained approximately 29.48% in six months, from around Rs 1,378 in mid-March 2026 to Rs 1,783.70 on 10 September 2026. That places this healthcare tech stock at rank 51 in our 101-stock screen, a solid move but not a runaway rally.

The other time frames give a more mixed picture of this healthcare tech stock. Here is how it has performed across periods in the screen:

Period	Return (%)	Rank (out of 101)
1 Month	1.70%	78
6 Months	29.48%	51
1 Year	22.11%	59
Since Listing (Dec 2024)	-6.17%	Not ranked

The since-listing figure is measured from the NSE listing price of Rs 1,900 on 19 December 2024, when the share opened at a 43% premium to its IPO price of Rs 1,329. Investors who bought on listing day are still slightly under water, while IPO allottees are sitting on a gain of roughly 34%.

There was no split or bonus in the window, so the 29% move in this healthcare tech stock is real price appreciation. The face value remains Rs 1 per share.

Why Did This Healthcare Tech Stock Rise 29% in 6 Months?

This healthcare tech stock rose 29% in six months because profits grew much faster than revenue, and because the TruBridge acquisition gave investors a clear path to a far larger business. Three triggers did most of the work.

1. FY26 Profit Jumped 48% on Margin Expansion

Inventurus Knowledge Solutions reported FY26 revenue of Rs 3,211 crore, up approximately 19% from Rs 2,703 crore in FY25. Net profit rose far faster, climbing approximately 48% to Rs 722 crore from Rs 486 crore.

The gap came from margins. The operating margin improved to 34.48% in FY26 from 30.42% a year earlier, as automation reduced the cost of each process handled. For a healthcare tech stock, that margin gain signals pricing power rather than just volume.

Q4 FY26 results, released in May 2026, kept the momentum going for this healthcare tech stock. Revenue rose around 18% in rupee terms and 13% in dollar terms, while quarterly profit reached approximately Rs 206 crore, up about 39% year on year.

2. The TruBridge Deal Lifted the Growth Outlook

On 23 April 2026, the US subsidiary of the company agreed to buy TruBridge, a US provider of billing and health record software, for USD 26.25 per share in cash. The enterprise value was approximately USD 557 million, funded mainly by a five-year loan of around USD 600 million from three global banks.

TruBridge brought roughly USD 347 million of revenue and USD 69 million of adjusted EBITDA, along with more than 1,500 clients, many of them rural and community hospitals. Management said the deal would add to earnings per share in FY27 and set a target of Rs 3,000 crore of EBITDA by FY30, roughly three times the level of calendar 2025.

The market liked the plan. This healthcare tech stock jumped as much as 9.5% intraday to Rs 1,572.80 the day after the announcement. The deal closed on 9 July 2026.

3. AI Products and Large Health System Wins

This healthcare tech stock has pitched an "AI plus human" model in which software handles routine coding, documentation and billing tasks while trained staff manage exceptions. During FY26 it launched an autonomous coding engine integrated with a leading US health record platform, and an agentic AI patient engagement tool called MyCareHub.

Client additions have also supported this healthcare tech stock. Management highlighted wins with a large California health system and Advocate Health in the Q1 FY27 call. These accounts matter because this healthcare tech stock earns most of its revenue from long, multi-year contracts that grow as clients add services.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

Inventurus Knowledge Solutions Share Price and Quarterly Financials

The quarterly numbers of this healthcare tech stock show a steady climb, with a small dip in Q1 FY27 margins due to one-time acquisition costs. The figures below are consolidated and include other income.

Quarter	Revenue (Rs Cr)	EBITDA (Rs Cr)	Operating Margin	Net Profit (Rs Cr)
Jun 2025 (Q1 FY26)	743	241	32.54%	152
Sep 2025 (Q2 FY26)	785	275	35.08%	181
Dec 2025 (Q3 FY26)	821	287	34.94%	183
Mar 2026 (Q4 FY26)	863	305	34.94%	206
Jun 2026 (Q1 FY27)	899	301	33.05%	194

In Q1 FY27, revenue grew approximately 21% year on year, EBITDA rose about 25% and net profit increased nearly 28%. Constant currency growth was a lower 12%, which means a weaker rupee added a meaningful part of the reported growth for this healthcare tech stock.

Profit fell about 6% from the March quarter because integration costs of roughly Rs 20 crore hit Q1 margins. Q2 FY27 will be the first quarter to show the combined business properly.

Is This Healthcare Tech Stock Expensive Now?

Yes, on trailing numbers this healthcare tech stock trades at a clear premium. It carries a PE of approximately 40 against an industry PE of about 18, and a price to book ratio of about 10.9.

Metric	Value
Current Market Price (11 Sep 2026)	Approximately Rs 1,757
Market Cap	Approximately Rs 30,749 Cr
PE Ratio (TTM)	40.03
Industry PE	17.93
Price to Book	10.92
Return on Equity	25.77%
Debt to Equity (pre-deal)	0.27
52-Week High / Low	Rs 1,933 / Rs 1,262

The premium for this healthcare tech stock reflects high returns on equity and consistent profit growth. Management has cited a decade of profitable growth with a PAT CAGR of about 46%.

On 11 September 2026, the Inventurus Knowledge Solutions share price opened lower and traded near Rs 1,757, down about 1.5% from the previous close of Rs 1,783.70. That is around 9% below the 52-week high of Rs 1,933 and about 39% above the 52-week low of Rs 1,262.

How Institutions Have Backed This Healthcare Tech Stock

Institutional ownership in this healthcare tech stock has risen steadily since listing. Foreign institutional investors lifted their stake from 5.38% in March 2025 to 8.01% in June 2026, while domestic institutions nearly doubled their holding from 4.02% to 7.50%.

Shareholder	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	63.72%	63.72%	63.72%	63.72%	63.72%
FIIs	6.50%	7.02%	7.56%	8.19%	8.01%
DIIs	4.33%	4.89%	6.06%	6.40%	7.50%
Public	22.88%	21.90%	20.29%	19.39%	18.55%
Others	2.57%	2.46%	2.37%	2.31%	2.22%

Promoter holding in this healthcare tech stock has stayed unchanged at 63.72%, which signals no fresh founder selling after the IPO. Several mutual funds hold the Inventurus Knowledge Solutions share, and retail holding has fallen as institutions absorbed supply.

FII holding slipped slightly in the June 2026 quarter, but the rise in DII holding more than offset it.

Key Risks for This Healthcare Tech Stock

The rally has real support, but this healthcare tech stock carries risks worth weighing.

Higher Debt After TruBridge

This healthcare tech stock was close to debt free before the deal, with a debt to equity ratio of 0.27. The USD 600 million loan changes that. Management expects net debt to settle near Rs 300 crore by FY30, but that depends on strong cash generation over the next few years.

TruBridge Revenue Reset

After closing, management said TruBridge revenue had been reset lower by around USD 40 million a year because of more conservative accounting and customer adjustments. That was not fully expected before the deal, and integration surprises of this kind can weigh on the Inventurus Knowledge Solutions share price.

Currency and US Policy Exposure

Almost all revenue of this healthcare tech stock comes from US clients. A stronger rupee would cut reported growth, as the gap between 21% rupee growth and 12% constant currency growth in Q1 FY27 shows. Changes in US healthcare reimbursement rules could also slow client spending.

AI Disruption and Competition

Agentic AI tools are pushing down the fees charged for billing and coding work across the industry. If pricing falls faster than this healthcare tech stock can automate, margins could come under pressure. Rival point solution vendors are also expanding into broader platforms that compete with this healthcare tech stock.

Rich Valuation

A PE near 40, more than twice the industry average, leaves little room for a weak quarter. Any delay in the FY30 EBITDA path could trigger a sharp correction in this healthcare tech stock.

Download the Univest iOS App or Univest Android App to track the Inventurus Knowledge Solutions share price live

Inventurus Knowledge Solutions Share: Analyst View

Analysts covering the company have turned more constructive since the TruBridge deal, largely because it is expected to add to earnings per share from FY27. The core investment case for this healthcare tech stock rests on three things: steady growth with existing US health systems, margin gains from automation, and cross-selling to the combined client base, which management sizes at around USD 575 million.

The debate around this healthcare tech stock is about the price already paid. Bulls argue that a business with returns on equity above 25% and profit growth near 30% deserves a premium. Bears point to the new debt, the TruBridge revenue reset and the pressure AI puts on outsourcing fees.

Inventurus Knowledge Solutions Share Price Target

The consensus Inventurus Knowledge Solutions share price target from nine analysts is approximately Rs 1,965. That implies about 12% upside from the current level near Rs 1,757, and is slightly above the 52-week high of Rs 1,933.

Beyond the consensus Inventurus Knowledge Solutions share price target, the key levels to watch are the 52-week high of Rs 1,933 on the upside and the April 2026 breakout zone near Rs 1,570 on the downside. A sustained move above the listing price of Rs 1,900 would also turn the since-listing return positive for this healthcare tech stock.

Targets for a healthcare tech stock are revised often as results unfold, so treat them as one input among many.

Conclusion

This healthcare tech stock rose about 29% in six months on the back of a 48% jump in FY26 profit, margin gains from automation and a transformational TruBridge acquisition. Institutions have been steady buyers of this healthcare tech stock and promoter holding has stayed firm.

The risks are just as clear: higher debt, a revenue reset at TruBridge, currency exposure and a valuation well above the industry. The Inventurus Knowledge Solutions share price is still below its listing price, a reminder that returns depend heavily on entry point. Q2 FY27 results, the first full quarter with TruBridge, will be the next real test for this healthcare tech stock.

Frequently Asked Questions

Which healthcare tech stock rose 29% in 6 months?

Ans. Inventurus Knowledge Solutions (NSE: IKS), also known as IKS Health, is the healthcare tech stock that gained approximately 29.48% in six months as of 10 September 2026. It ranked 51st among 101 large-cap and mid-cap NSE stocks screened.

Why did the Inventurus Knowledge Solutions share price rise?

Ans. The share rose on a 48% jump in FY26 net profit to Rs 722 crore, better operating margins and the acquisition of US-based TruBridge for an enterprise value of about USD 557 million. The deal is expected to add to earnings per share from FY27.

What were Inventurus Knowledge Solutions Q1 FY27 results?

Ans. Consolidated revenue rose approximately 21% year on year to Rs 899 crore and net profit grew about 28% to Rs 194 crore. Constant currency growth was 12%, and integration costs of around Rs 20 crore trimmed margins.

Is Inventurus Knowledge Solutions trading above its IPO price?

Ans. Yes, the share trades roughly 34% above its IPO price of Rs 1,329 based on the 10 September close. However, it is about 6% below its NSE listing price of Rs 1,900, so listing-day buyers are still slightly in the red.

What is the 52-week high and low of Inventurus Knowledge Solutions?

Ans. The 52-week high is Rs 1,933 and the 52-week low is Rs 1,262 on NSE. The share traded near Rs 1,757 on 11 September 2026, down about 1.5% for the day.

What is the Inventurus Knowledge Solutions share price target?

Ans. The consensus target from nine analysts is approximately Rs 1,965, implying about 12% upside from around Rs 1,757. Targets are estimates and can change after each quarterly result.

Is this healthcare tech stock overvalued?

Ans. It trades at a PE of approximately 40 versus an industry PE of about 18, which is a clear premium for a healthcare tech stock. That premium reflects high returns on equity and strong profit growth, but it leaves little room for disappointment.

What are the main risks for Inventurus Knowledge Solutions?

Ans. Key risks include higher debt from the TruBridge purchase, a lower-than-expected TruBridge revenue base, dependence on US clients and currency moves, and fee pressure from AI tools. A SEBI-registered advisor can help assess whether the stock suits your portfolio.